Holen Sie sich die Stockscreener-App
1.03
4.63%
-0.05
Handel nachbörslich:
1.06
0.03
+2.91%
Schlusskurs vom Vortag:
$1.08
Offen:
$1.09
24-Stunden-Volumen:
246.72K
Relative Volume:
1.40
Marktkapitalisierung:
$11.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.93M
KGV:
-0.7164
EPS:
-1.4378
Netto-Cashflow:
$-10.72M
1W Leistung:
-4.63%
1M Leistung:
-4.63%
6M Leistung:
-2.83%
1J Leistung:
-56.36%
1-Tages-Spanne:
$1.03
$1.10
1-Wochen-Bereich:
$1.03
$1.125
52-Wochen-Spanne:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.03 | 11.97M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 - TMX Newsfile
Phio Pharmaceuticals Corp (PHIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phio Pharmaceuticals Corp (PHIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phio Pharmaceuticals Corp (PHIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Corp (PHIO) Institutional Confidence - TradingKey
PHIO Q1 2026 Earnings: EPS Miss Widens as Clinical-Stage Biotech Continues R&D InvestmentEarnings Sentiment Score - newsline.com
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesDividend Earnings Report - newsline.com
PHIO Should I Buy - Intellectia AI
PHIO Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Reports ResultsProfit Inflection Point - newsline.com
Number of shareholders of Phio Pharmaceuticals Corp. – MUN:44R1 - TradingView
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as R&D Spending IntensifiesEarnings Growth Forecast - newsline.com
Phio Pharmaceuticals Slides 2.6% as Selling Pressure PersistsForce Index - newsline.com
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Biotech Reports No Revenue - The Legal Advocate
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.17Reversal Setup Alerts - newsline.com
Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech - Bez Kabli
PHIO Q1 2026 Earnings: EPS Misses Estimates Amid Continued Clinical Trials FocusRevenue Beat Analysis - The Legal Advocate
Skin cancer treatment PH-762: Phio live Q&A session May 28 - Stock Titan
Phio Pharmaceuticals Holds Steady Near Support Levels; PHIO Stock Consolidates in Narrow RangeMA Cross Alert - The Legal Advocate
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentInvestor Earnings Call - thelegaladvocate.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Research-Focused Biotech Maintains Development Pace - newsline.com
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026 - TMX Newsfile
Phio Pharmaceuticals (PHIO) Q1 2026 Results Miss Estimates — EPS $-0.34 vs $-0.24Product Mix - newser.com
Phio Pharmaceuticals Corp.Common Stock (NQ:PHIO) - FinancialContent
TradingKey - TradingKey
Skin cancer drug hits 65% response; doctor, CEO to discuss what's next - Stock Titan
MSN Money - MSN
Why Phio Pharmaceuticals (PHIO) could be the turning point you've been waiting for (-0.87%) 2026-05-07Fast Rising Picks - newser.com
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Phio Pharmaceuticals (NASDAQ: PHIO) boosts PH-762 spending as Q1 2026 loss grows - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - TMX Newsfile
Skin cancer drug trial wraps at Phio, FDA submission targets Q2 - Stock Titan
PHIO Q1'26 Earnings: EPS estimate is (0.23) USD - TradingView
Is Phio Pharmaceuticals (PHIO) stock forming a trend channel | Q4 2025: EPS Tops ViewsStrategic Review - Newser
Cancer drug developer Phio sets April 29 live Q&A on clinical progress - Stock Titan
Phio Pharmaceuticals (PHIO) Stock Resistance Rejection (Modest Decline) 2026-04-20Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):